The p53 pathway and apoptosis

Journal of Cellular Physiology

Volumn 181, Issue 2, 1999, Pages 231-239

  Burns, Timothy F ^a   El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; CELL GROWTH; GENE TARGETING; GROWTH REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW;

ANIMALS; APOPTOSIS; CELL CYCLE; GENES, P53; HUMANS; MODELS, BIOLOGICAL; PHOSPHORYLATION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032876814     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L     Document Type: Review

References (111)

1. Adams JM, Cory S. The Bcl-2 Protein Family: arbiters of Cell Survival. 1998. Science 281:322-325.
2. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. 1998. Stabilization of wild-type p53 by hypoxia-inducible factor 1a. Nature 392:405-408.
3. Ashkenazi A Dixit VM. 1998. Death Receptors: signaling and modulation. Science, 281:1305-1308.
4. Avantaggiati, ML, Ogryzko, V, Gardner, K, Giordano, A, Levine, AS, Kelly, K. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell, 89:1175-1184.
5. Banin, S, Moyal, L, Khostravi, R, Shieh, S-Y, Taya, Y, Anderson, CW, Chessa, L, Smorodinsky, NI, Prives, C, Shiloh, Y, Ziv, Y. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-77.
6. Bates, S, Phillips, AC, Clark, PA, Stott, F, Peters, G, Ludwig, RL, Vousden KH. 1998. p14ARF links tumour suppressors RB and p53. Nature 395:124-125.
7. Bennett M, MacDonald K, Chan S-W, Luzio JP, Simari R, Weissberg P. 1998. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282:290-293.
8. Brady HJ, Salomons GS, Bobeldijk RC, Berns AJ. 1996. T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J 15:1221-1230.
9. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557.
10. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649.
11. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501.
12. Caelles C, Helmberg A, Karin M. 1994. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370:220-223.
13. Canman CE., Wolff AC, Chen CY, Fornace AJJ, Kastan MB. 1994. The p53-dependent G1 cell cycle checkpoint pathway and ataxiatelangiectasia. Cancer Res 54:5054-5058.
14. Canman CE, Gilmer TM, Coutts SB, Kastan MB. 1995. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9:600-611.
15. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano DD. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677-1679.
16. Chiou SK, Rao L, White E. 1994. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 4:2556-25563.
17. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
18. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852.
19. Collins MK, Marvel J, Malde P, Lopez-Rivas A. 1992. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J Exp Med 176:1043-1051.
20. Delia D, Goi K, Mizutani S, Yamada T, Aiello A, Fontanella E, Lamorte G, Iwata S, Ishioka C, Krajewski S, Reed JC, Peirotti MA. 1997. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene 14:2137-2147.
21. Deng C, Zhang P, Harper JW, Elledge SJ, and Leder P. 1995. Mice lacking p21CIP1/Waf1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684.
22. de Stanchina E, McCurrach ME, Zindy F, Shieh S-Y, Ferbeyte G, Samulsen AV, Prives C, Roussel MF, Sherr CJ, Lowe SW. 1998. E1A signaling to p53 involves the p19ARF tumor suppressor. Genes Dev 12:2434-2442.
23. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. 1994. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8:2540-2551.
24. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, Bradely A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
25. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
26. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174.
27. El-Deiry WS. 1998. Regulation of p53 downstream genes. Seminars in Cancer Biol 8:345-357.
28. Evan G, Littlewood T. 1998. A matter of life and cell death. Science 281:317-321
29. Fakharzadeh SS, Trusko SP, George DL. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565-1569.
30. Fiscella M, Ullrich SJ, Zambrano N, Shields MT, Lin D, Lees-Miller SP, Anderson CW, Mercer WE, Appella E. 1993. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 8:1519-1528.
31. Froesch BA, Aime-Sempe C, Leber B, Andrews, D and Reed JC. 1999. Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain. JBC 274:6469-6475.
32. Fuchs EJ, McKenna KA, Bedi A. 1997. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32 beta. Cancer Res 57:2550-2554.
33. Giaccia AJ, Kastan MB. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12:2973-2983.
34. Gottlieb E, Lindner S, Oren M. 1996. Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells. Cell Growth Diff 3:301-310.
35. Gottlieb E, Oren M. 1998. p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. EMBO J 17:3587-3596.
36. Gu W, Shi X-L, Roeder RG. 1997. Synergistic activation of transcription by CBP and p53. Nature 387:819-822.
37. Haupt Y, Rowan S, Shaulian E, Vousden K, Oren M. 1995. Induction of apoptosis in HeLa cells by transactivation-deflcient p53. Genes Dev 9:2170-2183.
38. Haupt T, Barak Y, Oren M. 1996. Cell type specific inhibition of p53-mediated apoptosis by mdm2. EMBO J 15:1596-1606.
39. Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
40. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B. 1997. 14-3-3sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1:3-11.
41. Herzog K-H, Chong MJ Kapsetaki M, Morgan JI, Mckinnon PJ. 1998. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 280:1089-1091.
42. Hollstein M, Sidransky D, Vogelstein B, Harris CC 1991. p53 mutations in human cancers. Science 253:49-53.
43. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC. 1994. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551-3555.
44. Honda R, Tanaka H, Yasuda H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25-27.
45. Howes KA, Ransom N, Papermaster DS, Lasudry JG, Albert DM, Windle JJ. 1994. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev 8:1300-1310.
46. Hupp TR, Meek DW, Midgley CA, Lane DP. 1993. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res 21:3167-3174.
47. Hupp TR, Sparks A, Lane DP. 1995. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83:237-245.
48. Israeli D, Tessler E, Haupt Y, Elkeles A, Wilder S, Amson R, Telerman A, Oren M. 1997. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J 16:4384-4392.
49. Jayaraman L, Prives C. 1995. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the C-terminus. Cell 81:1021-1029.
50. Jones SN, Roe AE, Donehower LA, Bradley A. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208.
51. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-659.
52. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292-8297.
53. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. 1991. Participation of p53 in the cellular response to DNA damage. Cancer Res 51:6304-6311.
54. Kastan MB, Zhan Q, El-Diery W, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ. 1992. A mammalian cell-cycle checkpoint pathway utilizing p53 and gadd45 is defective in Ataxia-Telangiectasia. Cell 71:587-597.
55. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y Gabrielli B, Chan D Lees-Miller SP, Lavin MF. 1998. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 20:398-400.
56. Knudson, CM Tung KSK, Tourtellotte WG, Brown GAJ, Korsmeyer SJ. 1995. Bax-deficient mice with lymphoid hyperplasia and male germ-cell death. Science 270:96-99.
57. Kubbutat MH, Jones SN, Vousden KH. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
58. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. PNAS 89:7491-7495.
59. Lee S, Elenbass B, Levine A, Griffith J. 1995. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81:1013-1020.
60. Lees-Miller, SP Sakaguchi K, Ullrich S, Appella E, Anderson CW. 1992. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol 12:5041-5049.
61. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-852.
62. Malkin D, Li FP, Strong FC, Fraumeni JFJ, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238.
63. Marin MC, Hsu B, Meyn RE, Donehower LA, el-Naggar AK, McDonnel TJ. 1994.. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene 9:3107-3112.
64. Mayr GA, Reed M, Wang P, Wang Y, Schwedes JF, Tegtmeyer P. 1995. Serine phosphorylation in the NH2 terminus of p53 facilitates transactivation. Cancer Res 55:2410-2417.
65. McCurrach ME, Connor TMF, Knudson CM, Korsmeyer SJ, Lowe SW. 1997. Bas-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. PNAS 94: 2345-2349.
66. Meek DW. 1998. Multisite phosphorylation and the integration of stress signals at p53. Cell Signal 10(3):159-166.
67. Midgley CA, Lane DP. 1997. p53 protein stability in tumor cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179-1189.
68. Miyashita T, Reed JC. 1995. tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
69. Momand J, Zambetti GP, Olson DC, Geoge DL, Levine AJ. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivaton. Cell 69:1237-1245.
70. Montes de Oca Luna R, Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206.
71. Nagata S. 1997. Apoptosis by death factor. Cell 88:355-365.
72. Nunez G, Benedict MA, Hu Y, Inohara N. 1998. Caspases: the proteases of the apoptotic pathway. Oncogene 17:3237-3245.
73. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83.
74. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. 1993. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362:857-860.
75. Owen-Schaub LB, Zhang W, Cusack JC, Angel LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang W-W, Kruzel E, Radinsky R. 1995. Wild-type human p53 and a temperature sensitive mutant induce fas/APO1 expression. Mol Cell Biol 15:3032-3040.
76. Palmero I, Pantoja C, Serrano M. 1998. p19ARF links the tumour suppressor p53 to Ras. Nature 395:125-126.
77. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A. 1998. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699-703.
78. Polyak K, Waldman T, He T-C, Kinzler KW, Vogelstein B. 1996. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10:1945-1952.
79. Polyak K, Xia Y, Zweier JL, Kinzler KW, and Vogelstein B. 1997. A model for p53-induced apoptosis. Nature 389:300-305.
80. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
81. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
82. Rajah R, Valentinis B, Cohen P. 1997. Insulin like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53- and IGF-independent mechanism. JBC 272:12181-12188.
83. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH. 1996. Specific loss of apoptotic but not cell cycle arrest function in a human tumour derived p53 mutant. EMBO J. 15:827-838.
84. Ryan KM, Vousden KH. 1998. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. MCB 18:3692-3698.
85. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831-2841.
86. Sakamuro D, Sabbatini P, White E, Prendergast GC. 1997. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15: 887-898.
87. Samuelson AV, Lowe SW. 1997. Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins. PNAS 22:12094-12099.
88. Selivanova G, Iotsova V, Okan I, Fritsche M, Storm M, Groner B, Crafstorm RC, Wilman KG. 1997. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from p53 C-terminal domain. Nat Med 3:632-638.
89. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace AJ Jr, El-Deiry WS. 1998. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 58:1593-1598.
90. Sherr CJ. 1998. Tumor surveillance via the ARF-p53 pathway. Genes Dev 12:2984-2991.
91. Shieh S-Y, Ikeda M, Taya Y, Prives C. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
92. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. 1997. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11:3471-3481.
93. Stott F, Bates SA, James M, McConnell BB, Starborg M, Brookes S, Palmero I, Hara E, Vousden KH, Peters G. 1998.. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17:5001-5014.
94. Sun P, Dong P, Dai K, Hannon GJ, Beach D. 1998. P53-Independent Role of MDM2 in TGF-B1 Resistance. Science 282:2270-2272.
95. Thornberry NA, Lazebnik Y. 1998. Caspases: enemies within. Science 281:312-316.
96. Thut CJ, Goodrich JA, Tjian R. 1997. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 11:1974-1986.
97. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh S-Y, Taya Y, Prives C, Abraham RT. 1999. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13: 152-157.
98. Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. 1998. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell 3:293-304.
99. Vogelstein B, Kinzler KW. 1992. p53 function and dysfunction. Cell 70:523-526.
100. Walker KK, Levine AJ. 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 93:15335-15340.
101. Wang Y, Szekely L, Okan I, Klein G, Wiman KG. 1993. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma cell line. Oncogene 12:3427-3431
102. Waterman MJF, Stavridi ES, Waterman JLF, Halazonetis TD. 1998. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nature Genet 19:175-178.
103. Westphal CH, Rowan S, Schmaltz C, Elson A, Fisher DE, Leder P. 1997. atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat Genet 16:397-401.
104. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee PWK. 1998. DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394:700-704.
105. Wu GS, Burns TF, McDonald ER III, Jiang W, Meng R, Krantz ID, Kao G, Gan D-D, Zhou J-Y, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, El-Deiry WS. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet 17:141-143.
106. Xu Y, Baltimore D. 1996. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev, 10:2401-2410.
107. Yin Y, Terauchi Y, Solomon GG, Aizawa S, Rangarajan PN, Yazaki Y, Kadowaki T, Barrett JC. 1998. Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature 391:707-710.
108. Yuan Z-M, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Shioya H, Utsugisawa Y, Yokoyama K, Weichselbaum R, Shi Y, Kufe D. 1999. Role for p300 in Stabilization of p53 in the Response to DNA Damage. JBC 274:1883-1886.
109. Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.
110. Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC, Fornace AJ, Jr. 1999. Association with Cdc2 and inhibition of Cdc2/ Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 18:2892-2900.
111. Zindy F, Eischen CM, d Randle Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12:2424-2433.